ALLHAT education campaign
The National Heart, Lung and Blood Institute announces a three year, $3.7 mil. initiative to educate physicians and patients about hypertension findings from the ALLHAT trial. The study's main finding was that generic diuretic chlorthalidone is superior to Pfizer's calcium channel blocker Norvasc (amlodipine) and ACE inhibitors in preventing cardiovascular outcomes. The campaign, funded by NHLBI, will be implemented in collaboration with the National High Blood Pressure Education Program. Approximately 150 physicians in 34 states have completed training to lead educational sessions with physician peers. Educators will conduct one session per month and are expected to reach nearly 30,000 physicians by September 2006. Cardiologists have expressed concern about the translation of ALLHAT findings into clinical practice. (1"The Pink Sheet" June 27, 2005, p. 20)...
You may also be interested in...
Class labeling for reduction of cardiovascular outcomes based on blood pressure lowering should be applied to new classes of antihypertensives, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said
There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.
Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure
A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.